Novo Nordisk Ceases Wegovy Distribution on Hims & Hers Amidst Allegations of Misleading Marketing
In light of ongoing concerns, Novo Nordisk has terminated its association with Hims & Hers Health. The pharmaceutical giant cited allegations that the telehealth provider was distributing unauthorized replicas of Wegovy, their weight-loss medication.
The Danish company announced that due to these claims, Wegovy will no longer be accessible through Hims & Hers. This termination follows accusations that the San Francisco-based telehealth firm supplied counterfeit versions of Wegovy, potentially endangering patients.
Notably, this decision comes less than two months after both organizations publicized their intention to embark on a lasting partnership aimed at broadening obesity treatment availability.
The announcement led to a sharp decline in Hims & Hers' stock value, plummeting over $20, or around 31%, closing at $44.10.
Requests for comments from Hims & Hers have not yet been addressed.
Novo Nordisk had initiated Wegovy sales through telehealth platforms, including Hims & Hers, following a shortage. The goal was to steer customers away from unauthorized compounded variants by providing FDA-approved semaglutide.
A spokesperson from Novo Nordisk indicated that after more than a month into their collaboration, Hims & Hers had breached regulations against mass sales of compounded drugs disguised as 'customized' offerings. This unlawful marketing, they claimed, risked patient safety and prompted the severance of ties.
In March 2024, the FDA approved Wegovy for adults dealing with obesity, joining other weight management medications like Ozempic and Mounjaro. Recently, a surge in demand for GLP-1 drugs—used for both diabetes and weight management—has been noticed, with one in eight American adults reportedly using them, according to KFF.
The company also revealed that investigations found knock-off drugs sold by certain telehealth services and compounding pharmacies were being produced by foreign suppliers, many from China, and a notable portion hadn't been vetted by the FDA.
Expressing their concerns, Novo Nordisk emphasized that U.S. consumers should not be exposed to unreliable and potentially harmful foreign-made drug variants.
According to Dave Moore, Novo Nordisk's Executive Vice President, the firm will maintain Wegovy sales through other telehealth platforms that prioritize patient safety, including partnerships with companies like LifeMD and Ro.



Leave a Reply